Novo Nordisk A/S has finalized a partnership with Hims & Hers Health to distribute its weight loss drugs, Ozempic and Wegovy, directly through the telehealth platform, marking a pivotal resolution to their previous legal disputes. The agreement has led to a significant spike of over 50% in Hims & Hers stock, as both companies aim to expand access to FDA-approved treatments amidst rising competition. This collaboration could provide Novo Nordisk greater brand control and support Hims & Hers' growth in the obesity medication market, crucial as both companies navigate ongoing pricing pressures and market challenges.
“Novo Nordisk $NVO confirms deal to sell Ozempic and Wegovy weight loss drugs through Hims & Hers.”
“Novo Nordisk A/S and Hims & Hers Health Inc. will work together to sell obesity drugs, a sudden reversal after more than eight months of acrimony that culminated in a legal battle.”
“NOVO NORDISK WARNED BY FDA OVER ADVERSE EVENT DRUG DATA REPORTING. The US FDA issued a warning letter accusing the company of not complying with reporting requirements for postmarketing adverse event drug reports.”
“Hims & Hers saw its share prices jump by 57.4 percent week-on-week, with the rally primarily driven by its renewed partnership with Novo Nordisk, as well as analysts’ upgraded price targets for its stock.”
“Hims & Hers Health (HIMS) rose ~57% this week, marking its best-ever weekly advance after the telehealth firm ended a months-long dispute with Novo Nordisk (NVO) and agreed to sell the pharma giant’s brand-name weight-loss drugs on its platform.”
“Pomerantz LLP has launched an investigation into Novo Nordisk (NYSE:NVO) for potential securities fraud linked to its CagriSema Phase 3 trial results. The probe follows disappointing CagriSema data and a recent FDA warning letter regarding adverse event reporting practices.”
“The new legal scrutiny adds to existing regulatory questions and introduces an additional source of risk for current and prospective shareholders. For investors, the combination of a securities investigation, a recent FDA warning letter and trial disappointment concentrates attention on Novo Nordisk's disclosure practices, compliance controls and pipeline risk.”
“The stock has declined 23.4% over the past 30 days and 27.5% year to date, with a 49.8% drop over the past year and a 43.5% decline over three years, partly reflecting rising concern around its clinical and regulatory setbacks.”
“The Pomerantz probe sits on top of this as a potential overhang, even if it is only at the investigation stage. For existing holders, the key question is whether this marks a reset in market expectations around growth, pricing and risk tolerance for GLP-1 names such as Novo Nordisk...”
“TrumpRx launched last month with Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and AstraZeneca (AZN) agreeing to sell their products on the site for cash-paying customers as part of President Donald Trump’s Most Favored Nation (MFN) drug pricing policy.”
“Novo Nordisk is also partnering with a Chinese company to develop UBT251, a medicine that mimics the actions of GLP-1, GIP, and glucagon -- a triple agonist. In a recent phase 2 study in China, UBT251 posted a mean weight loss of up to 19.7% in just 24 weeks.”
“Hims & Hers shares... surged over 52% in the last week after the announcement of a new partnership with Novo Nordisk to sell Ozempic and Wegovy on its platform, resolving a dispute between the two companies.”